A high-efficiency induction of dopaminergic cells from human umbilical mesenchymal stem cells for the treatment of hemiparkinsonian rats

Cell Transplantation

Volumn 24, Issue 11, 2015, Pages 2251-2262

  Ko, Tsui Ling ^a   Fu, Yu Yi ^b   Shih, Yang Hsin ^c,d   Lin, Yi Hui ^e   Ko, Miau Hwa ^f   Fu, Tz Win ^c   Lin, Tzu Yung ^g   Hsiao, Hsiao Sheng ^a   Chu, Pei Ming ^f   Fu, Yu Show ^a,h  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NAN KAI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^h TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Dopaminergic cells; Human umbilical mesenchymal stem cells (HUMSCs); Nurr1; Parkinson s disease (PD); Transplantation

Indexed keywords

AMPHETAMINE; DOPAMINE; FIBROBLAST GROWTH FACTOR 8; NUCLEAR RECEPTOR RELATED FACTOR 1; OXIDOPAMINE; SONIC HEDGEHOG PROTEIN; TYROSINE 3 MONOOXYGENASE; NR4A2 PROTEIN, HUMAN;

ADULT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CORD BLOOD STEM CELL TRANSPLANTATION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIMIT OF QUANTITATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEM CELL GENE THERAPY; THERAPY EFFECT; ANIMAL; BIOSYNTHESIS; CELL CULTURE TECHNIQUE; CYTOLOGY; DISEASE MODEL; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TRANSPLANTATION; UMBILICAL CORD; WHARTON JELLY;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE; UMBILICAL CORD; WHARTON JELLY;

EID: 84945907660     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368914X685078     Document Type: Article

References (41)

1. Abasi, M.; Massumi, M.; Riazi, G.; Amini, H. The synergistic effect of beta-boswellic acid and Nurr1 overexpression on dopaminergic programming of antioxidant glutathione peroxidase-1-expressing murine embryonic stem cells. Neuroscience 222:404–416; 2012.
2. Arbuthnott, G.; Fuxe, K.; Ungerstedt, U. Central catecholamine turnover and self-stimulation behaviour. Brain Res. 27(2):406–413; 1971.
3. Baksh, D.; Yao, R.; Tuan, R. S. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25(6):1384–1392; 2007.
4. Can, A.; Karahuseyinoglu, S. Concise review: Human umbilical cord stroma with regard to the source of fetusderived stem cells. Stem Cells 25(11):2886–2895; 2007.
5. Castillo, S. O.; Baffi, J. S.; Palkovits, M.; Goldstein, D. S.; Kopin, I. J.; Witta, J.; Magnuson, M. A.; Nikodem, V. M. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell. Neurosci. 11(1–2):36–46; 1998.
6. Chen, L. H.; Chu, P. M.; Lee, Y. J.; Tu, P. H.; Chi, C. W.; Lee, H. C.; Chiou, S. H. Targeting protective autophagy exacerbates UV-triggered apoptotic cell death. Int. J. Mol. Sci. 13(1):1209–1224; 2012.
7. Chung, S.; Sonntag, K. C.; Andersson, T.; Bjorklund, L. M.; Park, J. J.; Kim, D. W.; Kang, U. J.; Isacson, O.; Kim, K. S. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur. J. Neurosci. 16(10):1829–1838; 2002.
8. Datta, I.; Mishra, S.; Mohanty, L.; Pulikkot, S.; Joshi, P. G. Neuronal plasticity of human Wharton’s jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells. Cytotherapy 13(8):918–932; 2011.
9. De Deurwaerdere, P.; L’Hirondel, M.; Bonhomme, N.; Lucas, G.; Cheramy, A.; Spampinato, U. Serotonin stimulation of 5-HT4 receptors indirectly enhances in vivo dopamine release in the rat striatum. J. Neurochem. 68(1):195–203; 1997.
10. Fu, Y. S.; Cheng, Y. C.; Lin, M. Y.; Cheng, H.; Chu, P. M.; Chou, S. C.; Shih, Y. H.; Ko, M. H.; Sung, M. S. Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro: Potential therapeutic application for Parkinsonism. Stem Cells 24(1):115–124; 2006.
11. Fu, Y. S.; Shih, Y. T.; Cheng, Y. C.; Min, M. Y. Transformation of human umbilical mesenchymal cells into neurons in vitro. J. Biomed. Sci. 11(5):652–660; 2004.
12. Hermanson, E.; Joseph, B.; Castro, D.; Lindqvist, E.; Aarnisalo, P.; Wallen, A.; Benoit, G.; Hengerer, B.; Olson, L.; Perlmann, T. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp. Cell Res. 288(2):324–334; 2003.
13. Hudson, A. L.; Lalies, M. D.; Silverstone, P. Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex. Can. J. Physiol. Pharmacol. 90(6):803– 809; 2012.
14. Hynes, M.; Rosenthal, A. Specification of dopaminergic and serotonergic neurons in the vertebrate CNS. Curr. Opin. Neurobiol. 9(1):26–36; 1999.
15. Jankovic, J.; Chen, S.; Le, W. D. The role of Nurr1 in the development of dopaminergic neurons and Parkinson’s disease. Prog. Neurobiol. 77(1–2):128–138; 2005.
16. Kim, J. H.; Auerbach, J. M.; Rodriguez-Gomez, J. A.; Velasco, I.; Gavin, D.; Lumelsky, N.; Lee, S. H.; Nguyen, J.; Sanchez-Pernaute, R.; Bankiewicz, K.; McKay, R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature 418(6893):50–56; 2002.
17. Le, W.; Conneely, O. M.; He, Y.; Jankovic, J.; Appel, S. H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73(5):2218–2221; 1999.
18. Le, W.; Pan, T.; Huang, M.; Xu, P.; Xie, W.; Zhu, W.; Zhang, X.; Deng, H.; Jankovic, J. Decreased NURR1 gene expression in patients with Parkinson’s disease. J. Neurol. Sci. 273(1–2):29–33; 2008.
19. Li, J. F.; Yin, H. L.; Shuboy, A.; Duan, H. F.; Lou, J. Y.; Li, J.; Wang, H. W.; Wang, Y. L. Differentiation of hUCMSC into dopaminergic-like cells after transduction with hepatocyte growth factor. Mol. Cell. Biochem. 381(1– 2):183–190; 2013.
20. Lin, Y. C.; Ko, T. L.; Shih, Y. H.; Lin, M. Y.; Fu, T. W.; Hsiao, H. S.; Hsu, J. Y.; Fu, Y. S. Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke 42(7):2045–2053; 2011.
21. Lindvall, O. Stem cells for cell therapy in Parkinson’s disease. Pharmacol. Res. 47(4):279–287; 2003.
22. Liu, H.; Wei, L.; Tao, Q.; Deng, H.; Ming, M.; Xu, P.; Le, W. Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson’s disease. Eur. J. Neurol. 19(6):870–875; 2012.
23. Liu, X.; Li, F.; Stubblefield, E. A.; Blanchard, B.; Richards, T. L.; Larson, G. A.; He, Y.; Huang, Q.; Tan, A. C.; Zhang, D.; Benke, T. A.; Sladek, J. R.; Zahniser, N. R.; Li, C. Y. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res. 22(2):321–332; 2012.
24. Mitchell, K. E.; Weiss, M. L.; Mitchell, B. M.; Martin, P.; Davis, D.; Morales, L.; Helwig, B.; Beerenstrauch, M.; Abou-Easa, K.; Hildreth, T.; Troyer, D.; Medicetty, S. Matrix cells from Wharton’s jelly form neurons and glia. Stem Cells 21(1):50–60; 2003.
25. Navailles, S.; Bioulac, B.; Gross, C.; De Deurwaerdere, P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson’s disease. Neurobiol. Dis. 38(1):136–143; 2010.
26. Navailles, S.; De Deurwaerdere, P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology 213(2–3):213–242; 2011.
27. Nekanti, U.; Rao, V. B.; Bahirvani, A. G.; Jan, M.; Totey, S.; Ta, M. Long-term expansion and pluripotent marker array analysis of Wharton’s jelly-derived mesenchymal stem cells. Stem Cells Dev. 19(1):117–130; 2010.
28. Piccini, P.; Lindvall, O.; Bjorklund, A.; Brundin, P.; Hagell, P.; Ceravolo, R.; Oertel, W.; Quinn, N.; Samuel, M.; Rehncrona, S.; Widner, H.; Brooks, D. J. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Ann. Neurol. 48(5):689–695; 2000.
29. Ribeiro, D.; Laguna Goya, R.; Ravindran, G.; Vuono, R.; Parish, C. L.; Foldi, C.; Piroth, T.; Yang, S.; Parmar, M.; Nikkhah, G.; Hjerling-Leffler, J.; Lindvall, O.; Barker, R. A.; Arenas, E. Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. Neurobiol. Dis. 49C:118– 127; 2012.
30. Sarugaser, R.; Lickorish, D.; Baksh, D.; Hosseini, M. M.; Davies, J. E. Human umbilical cord perivascular (HUCPV) cells: A source of mesenchymal progenitors. Stem Cells 23(2):220–229; 2005.
31. Saucedo-Cardenas, O.; Quintana-Hau, J. D.; Le, W. D.; Smidt, M. P.; Cox, J. J.; De Mayo, F.; Burbach, J. P.; Conneely, O. M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. USA 95(7):4013–4018; 1998.
32. Subramanian, A.; Shu-Uin, G.; Kae-Siang, N.; Gauthaman, K.; Biswas, A.; Choolani, M.; Bongso, A.; Chui-Yee, F. Human umbilical cord Wharton’s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. J. Cell. Biochem. 113(6):1886–1895; 2012.
33. Taghizadeh, R. R.; Cetrulo, K. J.; Cetrulo, C. L. Wharton’s Jelly stem cells: Future clinical applications. Placenta 32(Suppl 4):S311–S315; 2011.
34. Troyer, D. L.; Weiss, M. L. Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells 26(3):591–599; 2008.
35. Tsai, P. C.; Fu, T. W.; Chen, Y. M.; Ko, T. L.; Chen, T. H.; Shih, Y. H.; Hung, S. C.; Fu, Y. S. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s jelly in the treatment of rat liver fibrosis. Liver Transpl. 15(5):484–495; 2009.
36. Ungerstedt, U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl. 367:49–68; 1971.
37. Ungerstedt, U.; Arbuthnott, G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24(3):485–493; 1970.
38. Wang, H. S.; Hung, S. C.; Peng, S. T.; Huang, C. C.; Wei, H. M.; Guo, Y. J.; Fu, Y. S.; Lai, M. C.; Chen, C. C. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 22(7):1330–1337; 2004.
39. Zetterstrom, R. H.; Solomin, L.; Jansson, L.; Hoffer, B. J.; Olson, L.; Perlmann, T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276(5310):248–250; 1997.
40. Zetterstrom, R. H.; Solomin, L.; Mitsiadis, T.; Olson, L.; Perlmann, T. Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol. Endocrinol. 10(12):1656–1666; 1996.
41. Zetterstrom, R. H.; Williams, R.; Perlmann, T.; Olson, L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 41(1–2):111–120; 1996.